Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today provided an update from the Company on its progress and achievements in 2023.

Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today provided an update from the Company’s lead clinical program, L-130, a proprietary stabilized psilocin conjugate drug candidate. The Phase 1 study (NCT06035900) was an open label clinical trial in 10 normal and healthy individuals designed to determine the safety and pharmacokinetic parameters of L-130 after a single oral dose. All subjects were evaluated for impacts on cognition and anxiolytic effects on day 1, 7 and 28

Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the Company’s lead clinical asset, L-130, a proprietary stabilized psilocin conjugate drug candidate, recently surpassed the 12-month stability milestone with no signs of degradation. The Company believes the updated stability report for L-130 is significant, as to date, no manufacturer of psilocin has reported a formulation of psilocin stable enough to be administered in a shelf-stable orally available formul

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases announced today that Mathew Lee will join the organization as Chief Financial Officer, effective September 18, 2023.

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases announced that on August 30, 2023 it signed an amendment to the share purchase agreement to acquire a 100% interest in Altemia™ & Company, LLC (“Seller”) which includes all assets, know-how, intellectual property and commercial inventory of the Seller to manage patients suffering from Sickle Cell Disease (the “Amendment”) as originally announced on April 18, 2023.

Vancouver, British Columbia--(Newsfile Corp. - June 30, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today announced as a result of a review by the British Columbia Securities Commission, we are issuing the following press release to clarify our disclosure with respect to the acquisition of Altemia & Company, LLC ("Altemia") on April 18, 2023. The Company has also refiled the material change report with respect to the Altemia acquisition to reflect the information presented in this press release.

Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the initiation of a Phase 1, pharmacokinetic clinical study of L-130, a proprietary stabilized psilocin analogue drug candidate in healthy volunteers. The first-in-man, open-label study, conducted in Jordan under the authority of the Jordan Food and Drug Administration, will help determine the dose range of L-130 for a planned Phase 2 trial targeting the treatment of chronic cluster headaches (CCH), the most p

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the appointment of Baxter Phillips III, MBA, to the newly created position of Chief Operating Officer (COO) effective immediately. The position was created to provide additional executive leadership as Lobe Sciences continues its strategic transition to a diversified, fully integrated biopharmaceutical company preparing to launch its first commercial product, Altemia™, a medical food designed for patients with

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat orphan diseases today announced it has entered into a commercial distribution agreement for the supply and distribution of Altemia™ with Pentec Health, Inc. (“Pentec Health”), a nationwide provider of clinical nutrition and specialty care services addressing complex needs for patients. Altemia™ is Lobe’s proprietary formulation of emulsified docosahexaenoic acid ethyl ester (“DHA”) concentration designed for patients with sickle cell disea

Vancouver, British Columbia--(Newsfile Corp. - April 21, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today provides an update on its acquisition of the Vitamind Brand and intellectual property ("Vitamind") pursuant to an asset purchase agreement dated April 30, 2021 (the "Agreement").

VANCOUVER, BC / ACCESSWIRE / April 19, 2023 / The Power Play by The Market Herald has announced the release of new interviews with ARway, Silver Bullet Mines, Galantas Gold, Lobe Sciences, Northstar Gold and Rover Metals discussing their latest news.

Vancouver, British Columbia--(Newsfile Corp. - April 18, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today announced that it has signed a share purchase agreement to acquire a 100% interest in Altemia™ & Company, LLC ("Seller") which includes all assets, know-how, intellectual property and commercial inventory of the Seller (the "Transaction") to manage patients suffering from Sickle Cell Disease ("SCD"). The Seller has no current or long-term liabilities.

Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) -  Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") a North American Biopharmaceutical company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today announced that Philip Young, CEO and Executive Chairman, will present at the SEQUIRE CANNABIS & PSYCHEDELICS CONFERENCE, April 5th at 10:00AM EDT.

Dosing In Human Clinical Trial To Commence Within Weeks

By Richard Dal Monte

Vancouver, British Columbia--(Newsfile Corp. - February 21, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient-focused psychedelic-derived medicines for neurologic and brain disease today announced that its exclusive discovery and manufacturing partner Quality Chemical Laboratories LLC ("QCL") has initiated commercial formulation activities for L-130. QCL, in collaboration with Clearway Global, LLC, will prepare the chemical, manufacturing and control section of the investigational new drug application being filed later this year. Material produced at QCL will also be used in the recently announced Phase I/IIa study to evaluate L-130 as a treatment for chronic cluster headaches, a debilitating orphan disease.

Vancouver, British Columbia--(Newsfile Corp. - February 10, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient-focused psychedelic-derived medicines for neurologic and brain disease today announced a financing in the amount of USD $250,000.

Vancouver, British Columbia--(Newsfile Corp. - February 6, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today congratulated the people of Australia for the decision by the TGA (Therapeutic Goods Administration) to reschedule Psilocybin and MDMA so that trained physicians may prescribe the psychedelics for patients across the country.

Dr. Lauren R. Natbony to be Principal Investigator

Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced its Board of Directors voted to receive shares in Lobe in lieu of the traditional cash renumeration.

Vancouver, British Columbia--(Newsfile Corp. - January 18, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient focused psychedelic derived medicines for neurologic and brain disease today announced an updated overview for 2023.

Vancouver, British Columbia--(Newsfile Corp. - November 30, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced an update for its clinical development plans for its proprietary Psilocin based compound L-130.

Vancouver, British Columbia--(Newsfile Corp. - November 8, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") today announced that Philip Young, CEO and Executive Director, will present at the MONEYSHOW VIRTUAL EXPO, November 10th at 10:40AM EDT.

Appointment of Philip J. Young, CEO, as Board Chairman

Vancouver, British Columbia--(Newsfile Corp. - October 5, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that Baxter F. Phillips III has been appointed to the Board of Directors of the Company, effective October 3, 2022. Mr. Phillips has more than 20 years of experience leading multinational corporate strategy and finance in the biotechnology and pharmaceutical industry. As a member of the Company's Board of Directors, Mr. Phillips will also serve as the Chairman of the Audit Committees.

Resignation of Board Chairman, Jonathan Gilbert and Shares for Debt Transactions

Vancouver, British Columbia--(Newsfile Corp. - September 23, 2022) -  Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has incorporated Lobe Sciences Australia Pty Ltd., a 100% owned Australian subsidiary of the Company, to facilitate the three or more clinical trials in Australia with newly announced partner iNGENū Pty Ltd. The trials aim to evaluate Lobe's proprietary psilocin analogues L-130 or L-131. Australian Federal Government's Research & Development tax incentive program will provide rebates to Lobe for up to 43.5% on eligible expenditures for Research and Development conducted in Australia. The clinical trials are expected to commence in late 2022 or early 2023 pending local Regulatory approval.

Vancouver, British Columbia--(Newsfile Corp. - September 8, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease, today announced that it has closed a non-brokered private placement of units (the "Units") for gross proceeds of $1,347,500 (the "Offering").

VANCOUVER, BC, Sept. 1, 2022 /CNW/ - Trading resumes in:

Vancouver, British Columbia--(Newsfile Corp. - September 1, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into a term sheet contemplating convertible note financing bearing interest at 15% per annum with a term of 12 months (the "Convertible Notes") with Cantheon Capital ("Cantheon") for aggregate proceeds to the Company of up to USD$1,500,000 to conduct three clinical trials in Australia with newly announced partner iNGENū Pty Ltd. ("iNGENū"). The Convertible Notes will help fund the design and conduct of three clinical trials evaluating Lobe's proprietary psilocin analogues L-130 or L-131.

VANCOUVER, BC, Sept. 1, 2022 /CNW/ - The following issues have been halted by IIROC:

Vancouver, British Columbia--(Newsfile Corp. - August 19, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has updated its Corporate Slide Deck which among other initiatives, describes its plans for advancing the development of its psilocin analogues L-130 and L-131.

Vancouver, British Columbia--(Newsfile Corp. - August 10, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into an exclusive agreement with iNGENū Pty Ltd. ("iNGENū"), an Australian based Contract Research Organization (CRO), to design and conduct three or more clinical trials evaluating Lobe's proprietary psilocin analogues L-130 or L-131.

Vancouver, British Columbia--(Newsfile Corp. - July 19, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has filed a provisional patent for the preparation and use of its proprietary and stable psilocin related compounds.

Vancouver, British Columbia--(Newsfile Corp. - July 7, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biotechnology company committed to discovering and developing psychedelic derived medicines today announced it has developed its initial Phase 1 study plan intended to demonstrate the safety and appropriate dosing range for its proprietary new chemical entity; L-130. It is also announcing the acquisition of a second new chemical entity, L-131, which is expected to enter preclinical toxicity trials later this year or early in 2023.

Vancouver, British Columbia--(Newsfile Corp. - June 21, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biopsychedelics company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders, today announced an exclusive agreement with Clearway Global LLC ("Clearway").

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biopharmaceutical Company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders is reporting its roadmap for the remainder of 2022 and into 2023.

VANCOUVER, BC, June 9, 2022 /CNW/ - Trading resumes in:

Toronto, Ontario--(Newsfile Corp. - Le 9 juin/June 2022) - Lobe Sciences Ltd. (the "Issuer") has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every six (6) pre-consolidated common shares.

Vancouver, British Columbia--(Newsfile Corp. - June 9, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") announces that further to the Company's June 6, 2022, news release, the record date for the six for one consolidation has been adjusted to June 10, 2022.

VANCOUVER, BC, June 9, 2022 /CNW/ - The following issues have been halted by IIROC:

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") announces that its board of directors has authorized the implementation of a consolidation (the "Consolidation") of the Company's common shares (the "Shares") on the basis of one (1) post-Consolidation Share for every six (6) pre-Consolidation Shares, which will become effective on June 9, 2022 (the "Effective Date"). Neither the Company's name, nor its trading symbols, will change as a result of the Consolidation.

Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the April 27th and 28th KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing. REGISTER...

Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference to be held on...

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), based in Canada, a life sciences company focused on psychedelic medicines today announced that Philip Young, CEO, will present live at Virtual Investor Conferences.com on...

Vancouver, British Columbia--(Newsfile Corp. - March 30, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") announced today that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.

Vancouver, British Columbia--(Newsfile Corp. - March 23, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") announced today that Philip Young, CEO, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.

Vancouver, British Columbia--(Newsfile Corp. - March 22, 2022) -  Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") today announced that Philip Young, CEO and Director, will present at the MONEYSHOW VIRTUAL EXPO, March 23rd at 11:30AM EST.

Vancouver, British Columbia--(Newsfile Corp. - March 7, 2022) - Lobe Sciences Ltd. (the "Acquiror") announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 25, 2022, February 28, 2022, March 2, 2022 and March 3, 2022, it sold at total of 25,254,000 common shares in the capital of Ionic Brands Corp. (the "Issuer" and the common shares of the Issuer referred to as the "Common Shares"), which were originally issued to the Acquiror on February 3, 2022 as partial consideration for the sale to the Issuer of certain assets of the Acquiror.

Vancouver, British Columbia--(Newsfile Corp. - February 24, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (the "Acquiror") announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 22, 2022 and February 23, 2022, it sold a total of 4,500,000 common shares in the capital of Ionic Brands Corp. (the "Issuer" and the common shares of the Issuer referred to as the "Common Shares"), which were originally issued to the Acquiror on February 3, 2022 as partial consideration for the sale to the Issuer of certain assets of the Acquiror.

Vancouver, British Columbia--(Newsfile Corp. - February 22, 2022) - Lobe Sciences Ltd (CSE: LOBE) (OTCQB: LOBEF) today announced that Philip Young CEO will be attending the Q1 Virtual Investor Summit. During this presentation Lobe’s CEO Philip Young will provide highlights of the Company’s plans for for advancing into human clinical trials in 2022. The presentation will be webcast and an archived recording will be made available in the investors’ section of the Lobe Sciences website.

Vancouver, British Columbia--(Newsfile Corp. - February 16, 2022) - Lobe Sciences Ltd. (the "Acquiror") announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 15, 2022, it sold 5,800,000 common shares in the capital of Ionic Brands Corp. (the "Issuer" and the common shares of the Issuer referred to as the "Common Shares"), which were originally issued to the Acquiror on February 3, 2022 as partial consideration for the sale to the Issuer of certain assets of the Acquiror.

Vancouver, British Columbia--(Newsfile Corp. - February 14, 2022) - Lobe Sciences Ltd. (the "Acquiror") announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 11, 2022, it sold 8,000,000 common shares in the capital of Ionic Brands Corp. (the "Issuer" and the common shares of the Issuer referred to as the "Common Shares"), which were originally issued to the Acquiror on February 3, 2022 as partial consideration for the sale to the Issuer of certain assets of the Acquiror.

Vancouver, British Columbia--(Newsfile Corp. - February 3, 2022) - Lobe Sciences Ltd. (the "Acquiror") announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 3, 2022, it acquired 47,065,647 common shares in the capital of Ionic Brands Corp. (the "Issuer" and the common shares of the Issuer referred to as the "Common Shares"), pursuant to an annual cumulative preferential dividend on the 73,414,360 Series E Nonvoting Preferred Shares of the Issuer owned by the Acquiror (the "Series E Preferred Shares"), which were originally issued to the Acquiror on March 5, 2021 as partial consideration for the sale to the Issuer of certain assets of the Acquiror.

Vancouver, British Columbia--(Newsfile Corp. - January 7, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") today announced that Philip Young, CEO and Director, will present at the H.C. Wainwright BIOCONNECT Conference taking place January 10-14, 2022.

"Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder"

Vancouver, British Columbia--(Newsfile Corp. - December 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") is pleased to announce that it has received approval from OTC Markets Group Inc. ("OTCM") for its shares to trade on the OTCQB®. Lobe Sciences' common stock will commence trading on the OTCQB under the symbol "LOBEF" at the opening of the market on December 13, 2021.

The largest and most important Psychedelic Medicine Conference in the Southern Hemisphere

Vancouver, British Columbia--(Newsfile Corp. - November 15, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: LOBEF) ("Lobe" or the "Company") today announced that its common stock ticker will change from "GTSIF" to "LOBEF" and will commence trading under the symbol "LOBEF" in US markets at the opening of the market on November 15, 2021 and will continue to trade under the ticker symbol "LOBE" on the CSE.

Vancouver, British Columbia--(Newsfile Corp. - November 8, 2021) - Lobe Sciences (OTC Pink: GTSIF) today announced that Philip Young, CEO & Director will be attending the Q4 Virtual Investor Summit. Millions of people are experiencing the devastating, often long-term effects of mTBI (mild traumatic brain injury) and PTSD (post-traumatic stress disorder), with few, if any, effective treatments available. Our goal is to change that fact, and during this presentation, Philip Young, CEO & Director, will outline a path for the development of therapeutics for which Lobe Sciences intends to seek FDA approval in the United States, and similar approvals internationally.

Six Thought Leaders Across Arts, Technology, Academic and Industry Sectors to Advise on the Krysalistm Pod Immersive Treatment Experience

Vancouver, British Columbia--(Newsfile Corp. - October 5, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") today announced that Philip Young, CEO and Director, will present virtually at the BioFuture 2021 Conference taking place October 5-6, 2021, and will present virtually at the MoneyShow Virtual Expo taking place October 5-7, 2021

Vancouver, British Columbia--(Newsfile Corp. - October 4, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that the Company plans to develop and launch a global registry for the identification and long term management of current and former boxers with mTBI and PTSD in partnership with the World Boxing Association.

Combination Therapy with Psilocybin plus NAC (N-Acetylcysteine) Is Statistically Significantly Better Than Either Agent Alone or Placebo in a Rodent Model of mTBI and PTSD

Combination Therapy with Psilocybin plus NAC (N-Acetylcysteine) Is Statistically Significantly Better Than Either Agent Alone or Placebo in a Rodent Model of mTBI and PTSD

Vancouver, British Columbia--(Newsfile Corp. - September 27, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") today announced that Philip Young, CEO and Director, will present virtually at the Benzinga Healthcare Small Cap Conference taking place September 29-30, 2021.

Vancouver, British Columbia--(Newsfile Corp. - September 15, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") today announced that Philip Young, CEO and Director, will participate in a round table discussion at the Advances in Mental Health Psychedelics and Non-Psychedelics Conference presented by Maxim Group and hosed by M-Vest taking place Sept. 22, 2021.

Vancouver, British Columbia--(Newsfile Corp. - September 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to provide the following corporate update by CEO Philip Young, addressed to shareholders, investors and other stakeholders of the Company:

Vancouver, British Columbia--(Newsfile Corp. - September 10, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") today announced that Philip Young, CEO and Director, will present at the H.C. Wainwright 23rd Annual Global Investor Conference taking place Sept. 13-15, 2021.

Vancouver, British Columbia--(Newsfile Corp. - August 23, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce the appointment of Albert "Skip" Rizzo, Ph.D, to its Scientific Advisory Board.

Vancouver, British Columbia--(Newsfile Corp. - July 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce the appointment of Gilberto Jesús Mendoza, President of the World Boxing Association, to its Advisory Board.

Vancouver, British Columbia--(Newsfile Corp. - July 2, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") today announced that it became aware of certain promotional activities concerning its common stock on June 10, 2021. Issuer Services at OTC Markets Group (OTC Markets) notified the Company and supplied one (1) electronic newsletter (the "Newsletter") prepared by a third party - HotOtc as an example of such promotion. The Company was not aware of such Newsletter before receiving the copy from the OTC Markets.

Vancouver, British Columbia--(Newsfile Corp. - June 28, 2021) -  Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE: LOBE) (OTC Pink: GTSIF) is pleased to announce the appointment of Charles Grob, MD Investigator, The Lundquist Institute, and Professor of Psychiatry & Biobehavioral Sciences and Pediatrics, David Geffen School of Medicine at UCLA, to its Advisory Board.

Vancouver, British Columbia--(Newsfile Corp. - June 15, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") announced today that Philip Young, CEO and Director will be presenting virtually at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference taking place on Thursday, June 17, 2021.

Presentation on Tuesday, June 8 at 5:30 PM ET

Natural health products will be manufactured and packaged by HAVN Life

Vancouver, British Columbia--(Newsfile Corp. - May 12, 2021) - Lobe Sciences (CSE: LOBE) today announced that Philip Young, CEO and Director, will be attending the Q2 Virtual Investor Summit.

Vancouver, British Columbia--(Newsfile Corp. - May 6, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that it will be presenting at the Benzinga Global Small Cap Conference taking place on May 13-14, 2021. Philip Young, CEO and Director will be presenting on Thursday May 13th at 12:25 pm ET.

Addition of consumer packaged goods ("CPG") line of functional mushroom products further expands Lobe's operations and reach across the psychedelic space

PCT filing further strengthens the Company's intellectual property portfolio

Vancouver, British Columbia--(Newsfile Corp. - April 28, 2021) -  Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce it has entered into a non-binding letter of intent dated April 27, 2021 (the "Agreement") with Core One Labs Inc. (CSE: COOL) ("Core One Labs") to pursue the formation of a joint venture involving the development, regulatory approval and marketing of biosynthetic psilocybin and other psychedelic compounds (the "Joint Venture").

Development of Krysalis(TM) Therapeutic Pod to Deliver Headset-free Virtual Experience with Biometric Monitoring

Appointment of Dr. Kelmendi, Assistant Professor of Psychiatry at Yale University and co-founder of the Yale Psychedelic Science Group, brings another experienced medical professional to Lobe's advisory team.

Lobe invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference

Vancouver, British Columbia--(Newsfile Corp. - April 6, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce the appointment of Mr. Ilan Hayman, B.IS, ITIL Cert, M. ProjMngt to its Advisory Board.

Vancouver, British Columbia--(Newsfile Corp. - March 31, 2021) -  Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce it has become an official Enterprise Member of the NFL Alumni Association.

Vancouver, British Columbia--(Newsfile Corp. - March 29, 2021) - Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE: LOBE) (OTC Pink: GTSIF) is pleased to announce the Company has been added to the Horizons Psychedelic Stock Index ETF ("PSYK" or the "ETF") and its underlying index, the Horizons North American Psychedelics Index (the "Index").

Strategic sale of non-core assets by Lobe adds non-dilutive capital and shareholder value

Vancouver, British Columbia--(Newsfile Corp. - March 3, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce the appointment of Bart Oates Esq., President of the NFL Alumni Association, to its Advisory Board.

Vancouver, British Columbia--(Newsfile Corp. - February 24, 2021) -  Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at "The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference", a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

The transaction value of approximately $32,000,000 will significantly improve Lobe's balance sheet with non-dilutive capital and will provide immediate shareholder value

Vancouver, British Columbia--(Newsfile Corp. - February 22, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") announces that Philip Young, CEO and Director, will be interviewed on Tuesday, February 23rd, 2021 at 1:00 pm EST by broadcast journalist Christine Corrado of Proactive Investors, a leading multi-media news organization, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt, and London.

Proprietary spray delivers micro doses of psilocybin or N-acetylcysteine for treatment of PTSD and traumatic brain injury

Vancouver, British Columbia--(Newsfile Corp. - February 12, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that it has retained Jolt Communications LLC ("Jolt") to lead its investor relations efforts.

Appointment of Philip Young as CEO and director adds a seasoned executive with a track record of new device and therapeutics development, FDA/regulatory approvals, capital markets, M&A and operational success

Appointment of Michael Petter to the Board brings another seasoned board member with strong industry, capital markets and strategic planning expertise.

Vancouver, British Columbia--(Newsfile Corp. - January 6, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce, that due to strong investor demand, it has further upsized its previously announced non-brokered private placement of units (the "Units") from $2,700,000 to $3,445,847 (the "Offering") and has completed a second and final tranche closing, raising gross proceeds of $1,118,747 (the "Second Tranche Closing"). The Second Tranche Closing consisted of the issuance of an aggregate of 11,187,475 Units at a price of $0.10 per Unit. Together with the first closing, which was announced on December 24, 2020, the Company has raised total gross proceeds of $3,445,847 pursuant to the Offering, through the issuance of an aggregate of 34,458,475 Units.

Vancouver, British Columbia--(Newsfile Corp. - December 24, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company"), is pleased to announce that it has upsized its previously announced non-brokered private placement of units (the "Units") from $2,000,000 to up to $2,700,000 (the "Offering") and has completed a first closing raising gross proceeds of $2,327,100 (the "First Tranche Closing"). The First Tranche Closing consisted of the issuance of an aggregate of 23,271,000 Units at a price of $0.10 per Unit.

Vancouver, British Columbia--(Newsfile Corp. - December 14, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that it intends to raise up to Cdn$2,000,000 (the "Offering") through a non-brokered private placement of up to 20,000,000 units (the "Units") at a price of Cdn$0.10 per Unit.

Appointment of Jonathan Gilbert as Executive Chairman allows Lobe to capitalize on his significant capital markets experience

Vancouver, British Columbia--(Newsfile Corp. - December 3, 2020) -  Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that it has engaged VisionWorks Engineering of San Diego, CA to commence engineering work to complete and test a proof of concept prototype of its nasal mist device.

Signed LOI for CAD$23 million sale to Ionic provides shareholder value

Vancouver, British Columbia--(Newsfile Corp. - November 30, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine ("NAC") for the treatment of mild traumatic brain injury/concussion ("mTBI") with post-traumatic stress disorder ("PTSD"). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

Lobe Sciences unveils new corporate name and logo as part of an extensive rebranding initiative, reflective of the Company's focus on psychedelic medicines

Toronto, Ontario--(Newsfile Corp. - Le 12 novembre/November 12, 2020) - GreenStar Biosciences Corp. has announced a name and symbol change to Lobe Sciences Ltd. (LOBE)